Symbolbild · KI-generiert
Aura Biosciences, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs) for the treatment of cancer. The focus is on uveal melanoma and other solid tumours.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Aura Biosciences, Inc. | AURA | NASDAQ | 725 Mio. USD |
| Monopar Therapeutics Inc. | MNPR | NASDAQ | 726 Mio. USD |
| Aclaris Therapeutics, Inc. | ACRS | NASDAQ | 726 Mio. USD |
| Candel Therapeutics, Inc. | CADL | NASDAQ | 733 Mio. USD |
| Bright Minds Biosciences Inc. | DRUG | CSE | 715 Mio. USD |
| Pharming Group N.V. ADS, each representing 10 ordinary shares | PHAR | NASDAQ | 712 Mio. USD |
| Faeth Therapeutics, Inc. | FTH | NASDAQ | 702 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.